NDT Advance Access originally published online on April 16, 2007
Nephrology Dialysis Transplantation 2007 22(7):1815-1819; doi:10.1093/ndt/gfm224
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Are we overestimating left ventricular abnormalities in end-stage renal disease?
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, Scotland, UK
Correspondence and offprint requests to: Dr Patrick B. Mark, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, Scotland, UK. Email: p.mark@clinmed.gla.ac.uk
Keywords: cardiomyopathy; dialysis; echocardiography magnetic resonance imaging; end stage renal failure; left ventricular hypertrophy
| The first 150 words of the full text of this article appear below. |
| Introduction |
|---|
Uraemic cardiomyopathy, defined by the presence of left ventricular hypertrophy (LVH), left ventricular (LV) dilatation or LV systolic dysfunction (LVSD), is reported to be a predictor of premature cardiovascular mortality in patients with end-stage renal disease (ESRD) [1]. Each of these LV abnormalities cumulatively confers a poorer long term prognosis [2]. LV function, dimensions and geometry have conventionally been assessed by echocardiography. Echocardiography is well established, portable and widely available and therefore will remain a vital clinical tool. However, echocardiography has drawbacks, including operator-dependence and difficulty in obtaining satisfactory acoustic windows. A major technological limitation of echocardiography is the geometric assumption required to calculate LV mass and function. Using conventional M-mode echocardiography to assess LV mass by the Penn [3] or ASE formulae [4], ventricular dimensions are measured in the minor axis and then volumes estimated from the cube of these values,
| Comparisons between echocardiography and cardiac magnetic resonance imaging for measurement of LV dimensions |
|---|
| Uraemic cardiomyopathy as assessed by cardiac magnetic resonance imaging |
|---|
| Can CMR allow us to improve echocardiographic methods in patients with ESRD? |
|---|
| Improvements to echocardiographic technique for assessment of left ventricular mass |
|---|
| Limitations of CMR |
|---|
| Implications for treatment of uraemic cardiomyopathy |
|---|
This article has been cited by other articles:
![]() |
P. Machek, T. Jirka, U. Moissl, P. Chamney, and P. Wabel Guided optimization of fluid status in haemodialysis patients Nephrol. Dial. Transplant., September 30, 2009; (2009) gfp487v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Patel, P. B. Mark, N. Johnston, E. McGregor, H. J. Dargie, and A. G. Jardine Renal Transplantation Is Not Associated with Regression of Left Ventricular Hypertrophy: A Magnetic Resonance Study Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1807 - 1811. [Abstract] [Full Text] [PDF] |
||||

